Warning: due to the large number of participants, plenary sessions taking place in the amphitheatre Bordeaux

will be simultaneouly broadcast in the adjacent amphitheatre Havane.

        

 

Monday, 22 April 2024
S1 17:00 > 19:00 OPENING CEREMONY AMPHITHEATRE BORDEAUX
  • Chairman : K. Kenneth FISCHBECK (Bethesda, USA)
17:00 S1L1 Welcome ceremony > AFM-Téléthon President> Myology Presidents > L. Laurence TIENNOT-HERMENT (Paris, France), J. John VISSING (Copenhaghen, Denmark), A. Annemieke AARTSMA-RUS (Leiden, The Netherlands) 17:30 S1L2 Opening lecture 1: nucleoside-modified mrna-lnp therapeutics > D. Drew WEISSMAN (Philadephia, USA) Co-laureate of the Nobel Prize in Physiology or Medicine 2023 18:15 S1L3 Opening Lecture 2 : The road to gene therapy for DMD > J. Jeffrey CHAMBERLAIN (Seattle, USA)
B1 19:00 > 21:00 MEET AND GREAT TIME Hall Havane AB
Tuesday, 23 April 2024
S2 08:30 > 10:00 PLENARY SESSION // MYOGENESIS AMPHITHEATRE BORDEAUX
  • Chairmen : B. Bénédicte CHAZAUD (Lyon, France), F. Fabrice CHRÉTIEN (Paris, France)
08:30 S2L1 Muscle stem and niche cell dynamics in pathology > S. Shahragim TAJBAKHSH (Paris, France) 09:00 S2L2 Discovery & Clinical Validation of Nutritional Activators of Muscle Stem Cells > J. Jérôme FEIGE (Lausanne, Switzerland) 09:30 S2L3 The histone variant H2A.Z is required for DNA repair in muscle fibers and prevents premature aging > E. Edwige BELOTTI (Lyon, France) 09:45 S2L4 Contribution of Insulin-Like Growth Factor-I secreted from Fibro-Adipogenic Progenitors to Skeletal Muscle Regeneration > Y. Yangyi LUO (Gainesville, USA)
B2 10:00 > 10:30 COFFEE BREAK AND VISIT OF THE EXHIBIT HALL AND POSTER ROOM Hall Havane AB
S3 10:30 > 12:00 PARALLEL SESSION 1 // MUSCLE FIBROSIS / AGEING AMPHITHEATRE BORDEAUX
  • Chairman : G. Gillian BUTLER-BROWNE (Paris, France)
10:30 S3L1 Development of Myoscaffolds as a Platform to Interrogate Stem Cell Interaction with the Native Environment > R. Rachelle CROSBIE (Los Angeles, USA) 11:00 S3L2 Macrophage derived Spp1 maintains a novel stromal cell population that contributes to intramuscular fat in dystrophic muscle > M. Melissa SPENCER (Los Angeles, USA) 11:30 S3L3 Cellular actors and ECM components of human fibrosis in myopathies > C. Capucine TROLLET (Paris, France) 11:45 S3L4 Targeting FAP to reduce fibrosis in DMD: a rationale for a preclinical therapeutic trial in the GRMD dog model. > I. Inès BARTHÉLÉMY (Paris, France)
S4 10:30 > 12:00 PARALLEL SESSION 2 // CONGENITAL MYOPATHIES AMPHITHEATRE HAVANE
  • Chairman : I. Isabelle MARTY (Grenoble, France)
10:30 S4L1 Congenital myopathies > J. James DOWLING (Toronto, Canada) 11:00 S4L2 Congenital myopathies in adulthood > N. Nicol VOERMANS (Nijmegen, Netherlands) 11:30 S4L3 ASC-1 related myopathy reveals transcriptional co-activation as a new regulator of myogenesis: expanding the molecular spectrum and identifying the mechanisms of an emerging congenital myopathy. > A. Ana FERREIRO (Paris, France) 11:45 S4L4 Ultrarare CACNA1S congenital-myopathies pharmacological treatment through HiPSC-based Drug repurposing > R. Reem BOU AKAR (Créteil, France)
SYMPO1 12:00 > 13:00 INDUSTRY SYMPOSIUM // SAREPTA - A Deep Dive Into LGMDs: Disease, Diagnosis, and the Developing Treatment Landscape 352 A+B
  • Chairman : E. Erik NIKS (Leiden, The Netherlands)
  • Speakers : G. Giacomo COMI (Milan, Italy), L. Linda LOWES (Columbus, Ohio State, USA), E. Erik NIKS (Leiden, The Netherlands)
SYMP1L1 Overview of Limb-Girdle Muscular Dystrophies: Exploring the underlying pathology > E. Erik NIKS (Leiden, The Netherlands) SYMP1L2 The Evolving Diagnostic Process: Accurate diagnosis is needed to identify management opportunities > G. Giacomo COMI (Milan, Italy) SYMP1L3 Exploring New Therapies: Investigational SRP-9003 for LGMD2E/R4 > L. Linda LOWES (Columbus, Ohio State, USA) SYMP1L4 Q&A session
SYMPO2 13:00 > 14:00 INDUSTRY SYMPOSIUM // LUPIN - Myotonia: should we reach a consensus on patient needs? 351
  • Chairman : J. Jordi DIAZ-MANERA (Newcastle Upon Tyne, UK)
  • Chairman : G. Guillaume BASSEZ (Paris, France)
  • Speakers : J. Jordi DIAZ-MANERA (Newcastle Upon Tyne, UK), V. Valeria SANSONE (Milan, Italy), B. Benedikt SCHOSER (Munich, Germany)
13:00 SYMP2L1 Introduction and overview of myotonic disorders > G. Guillaume BASSEZ (Paris, France) 13:10 SYMP2L2 Living with myotonia: do we understand patients’ needs? > J. Jordi DIAZ-MANERA (Newcastle Upon Tyne, UK) 13:30 SYMP2L3 Debate – expert opinions on myotonia in myotonic dystrophies (DM) and non-dystrophic myotonia (NDM) > G. Guillaume BASSEZ (Paris, France), V. Valeria SANSONE (Milan, Italy), B. Benedikt SCHOSER (Munich, Germany) 13:55 SYMP2L4 Key takeaways and close > V. Valeria SANSONE (Milan, Italy)
B3 13:00 > 14:00 LIGHT LUNCH BUFFET (OFFERED) AND VISIT OF THE EXHIBIT HALL AND POSTER ROOM Hall Havane AB
S5 14:00 > 15:00 YOUNG INVESTIGATORS SYMPOSIUM AMPHITHEATRE BORDEAUX
  • Chairmen : S. Serge BRAUN (Evry, France), T. Thierry TOURSEL (Evry, France)
14:00 S5L1 Muscle targeted gene therapy to cure BIN1 centronuclear myopathy > J. Jacqueline JI (Illkirch-Graffenstaden, France) 14:15 S5L2 RNA-sequencing of Type II SMA paravertebral muscle after treatment reveals distinct molecular subtypes. > F. Fiorella GRANDI (Paris, France) 14:30 S5L3 The damaged lysosome is a therapeutic target for combined therapy in Duchenne muscular dystrophy > A. Abbass JABER (Evry, France) 14:45 S5L4 Deciphering the consequences of SORBS1 mis-splicing in myotonic dystrophy type 1 > M. Morgan GAZZOLA (Corbeil-Essonnes, France)
S6 15:00 > 15:20 LATE BREAKING NEWS AMPHITHEATRE BORDEAUX
  • Chairman : S. Serge BRAUN (Evry, France)
15:00 S6L1 First data of the phase I/II part of the clinical trial of GNT0004 AAV8-μdystrophin gene therapy in ambulant DMD boys > F. Francesco MUNTONI (London, United Kingdom)
RT 15:20 > 16:00 Duchenne gene therapy: lessons learned and future directions - Round table discussion AMPHITHEATRE BORDEAUX
  • Chairman : A. Annemieke AARTSMA-RUS (Leiden, The Netherlands)
  • Speakers : J. Jeff CHAMBERLAIN (Seattle, USA), E. Eugenio MERCURI (Rome, Italy), F. Francesco MUNTONI (London, United Kingdom)
B4 16:00 > 16:30 COFFEE BREAK AND VISIT OF THE EXHIBIT HALL AND POSTER ROOM Hall Havane AB
S7 16:30 > 18:00 PARALLEL SESSION 1 // SMA / NOVEL THERAPIES AMPHITHEATRE BORDEAUX
  • Chairman : J. Judith MELKI (Le Kremlin-Bicetre, France)
16:30 S7L1 New treatment in Spinal Muscular Atrophy > L. Laurent SERVAIS (Oxford, UK) 17:00 S7L2 Improved understanding of SMA and development of further treatment strategies > A. Arthur BURGHES (Columbus OH, United States) 17:30 S7L3 Bi-regional newborn screening program for spinal muscular atrophy in France linked to a nationwide strategy for standardized treatment and follow-up > V. Vincent LAUGEL (Strasbourg, France) 17:45 S7L4 LSD1/PRMT6-targeting gene therapy to attenuate androgen receptor toxic gain-of-function ameliorates SBMA phenotypes in flies and mice. > M. Maria PENNUTO (Padova, Italy)
S8 16:30 > 18:00 PARALLEL SESSION 2 // FSHD AMPHITHEATRE HAVANE
  • Chairmen : S. Sabrina SACCONI (Nice, France), S. Silvere VAN DER MAAREL (Leiden, The Netherlands)
16:30 S8L1 FSHD: Clinical Manifestation and Therapeutic Prospects > R. Rabi TAWIL (Rochester, USA) 17:00 S8L2 Decoding DUX4: understanding a trendy landscape of FSHD pathogenesis > A. Alberto ROSA (Cordoba, Argentina) 17:30 S8L3 Exchange of subtelomeric regions between chromosomes 4q and 10q: a novel way to revert the FSHD genotype and phenotype > A. Anna SCHWAGER (Villejuif, France) 17:45 S8L4 Targeting muscle degeneration in FSHD: insights from patients’ muscle stem cell niche to unlock disease mechanisms > L. Lorena DI PIETRO (Rome, Italy)
SYMPO3 18:00 > 19:00 INDUSTRY SYMPOSIUM // EDGEWISE - Protecting and preserving dystrophic muscle: The roles of exercise and pharmacological protection against contraction-induced injury 352 A+B
  • Chairman : J. Joanne DONOVAN (Boston, MA, United States)
SYMP3L1 Physical exercise and muscle damage in BMD > J. John VISSING (Copenhaghen, Denmark) SYMP3L2 Development of a cycle training paradigm to improve exercise capacity and pathophysiology in boys with DMD > T. Tanja TAIVASSALO (Orlando, FL, United States) SYMP3L3 Targeting Protection against Contraction-Induced Injury in BMD: An Overview of the EDG-5506 Clinical Program > J. Joanne DONOVAN (Boston, MA, United States)
Wednesday, 24 April 2024
S9 08:30 > 10:00 PLENARY SESSION // MUSCLE, SPORT, EXERCISE AMPHITHEATRE BORDEAUX
  • Chairmen : X. Xavier BIGARD (Ugine, France), N. Nicoline VOET (Wageningen, The Netherlands)
08:30 S9L1 Sports-related Acute Muscle Strain Injury and its Regeneration > M. Michael KJAER (Copenhagen, Denmark) 09:00 S9L2 Is it feasible to train all persons with neuromuscular diseases irrespective of disease type and severity? > J. John VISSING (Copenhaghen, Denmark) 09:30 S9L3 Muscle-to-brain communication under voluntary and forced exercise training applied in the context of obesity in mice. > A. Antoine DELPIERRE (Mons, Belgium) 09:45 S9L4 Thyroid hormone regulates skeletal muscle physiology and affects physical exercise efficiency > M. Monica DENTICE (Naples, Italy)
B5 10:00 > 10:30 COFFEE BREAK AND VISIT OF THE EXHIBIT HALL AND POSTER ROOM Hall Havane AB
S10 10:30 > 12:00 PARALLEL SESSION 1 //CMT & NEUROPATHIES AMPHITHEATRE BORDEAUX
  • Chairman : S. Shahram ATTARIAN (Marseille, France)
10:30 S10L1 Current treatments and new perspectives in Charcot-Marie-Tooth neuropathies > D. Davide PAREYSON (Milano, Italy) 11:00 S10L2 Charcot-Marie-Tooth disease: an overview of genetic and phenotypic variability > T. Tanya STOJKOVIC (Paris, France) 11:30 S10L3 SCREEN4PN: Efficient Evaluation Of Therapeutic Compounds For Charcot-Marie-Tooth Disease Using Patient-Derived Induced Motor Neurons and Neuromuscular Organoids > V. Vincent TIMMERMAN (Antwerpen, Belgium) 11:45 S10L4 Revisit Of Patients With Phenotypic Hereditary Polyneuropathy Without Genetic Confirmation > L. Louise Sloth KODAL (Copenhagen, Denmark)
S11 10:30 > 12:00 PARALLEL SESSION 2 // LGMD AMPHITHEATRE HAVANE
  • Chairman : J. Jorge A. BEVILACQUA (Santiago, Chili)
10:30 S11L1 Clinical trial readiness in limb girdle muscular dystrophies > J. Jordi DIAZ-MANERA (Newcastle Upon Tyne, UK) 11:00 S11L2 Development of gene therapy for three prevalent forms of LGMD > E. Evelyne GICQUEL (Evry-Courcouronnes, France) 11:30 S11L3 Biallelic variants in SNUPN cause a limb girdle muscular dystrophy with myofibrillar-like features > A. Alberto DAMBORENEA (Donostia-San Sebastián, Spain) 11:45 S11L4 Unraveling a Novel Form of Muscular Dystrophy Caused by Recessive SNUPN Mutations > M. Marwan NASHABAT (Istanbul, Turkey)
SYMPO4 12:00 > 13:00 INDUSTRY SYMPOSIUM // ITALFARMACO - New Insights and Clinical Outcomes in Duchenne Muscular Dystrophy 352 A+B
  • Chairmen : I. Isabelle DESGUERRE (Paris, France), F. Francesco MUNTONI (London, United Kingdom)
SYMP4L1 The Role of HDAC Inhibition as a Therapeutical Target in DMD > A. Annemieke AARTSMA-RUS (Leiden, The Netherlands) SYMP4L2 Assessing Milestones & Disease Progression in DMD > E. Eugenio MERCURI (Rome, Italy)
B6 13:00 > 14:30 LIGHT LUNCH (OFFERED) AND VISIT OF THE EXHIBIT HALL Hall Havane AB
SYMPO5 13:30 > 14:30 INDUSTRY SYMPOSIUM // PFIZER - Duchenne Muscular Dystrophy: Looking to the Horizon 351
  • Chairman : E. Eugenio MERCURI (Rome, Italy)
SYMP5L0 Welcome & Introduction > E. Eugenio MERCURI (Rome, Italy) SYMP5L1 A Closer Look at DMD > V. Volker STRAUB (Newcastle Upon Tyne, UK) SYMP5L2 Current and Developing Approaches to Treating DMD > A. Annemieke AARTSMA-RUS (Leiden, The Netherlands) SYMP5L3 What Lies on the Horizon of DMD Clinical Research? > E. Eugenio MERCURI (Rome, Italy) SYMP5L4 Final Discussion and Q&A With Audience
S12 14:30 > 16:00 PLENARY SESSION // POSTER FLASH SESSION AMPHITHEATRE BORDEAUX
  • Chairmen : E. Edoardo MALFATTI (Paris, France), F. France PIETRI-ROUXEL (Paris, France)
14:30 S12L1 A CRISPR-based mouse model of TPM3-related Congenital Fiber Type Disproportion (CFTD) recapitulates key features of the disease. > M. Matthias LAMBERT (Boston, USA) 14:33 S12L2 ME/CFS and Long COVID-19 Patient Sera induce Hypermetabolism while Impairing Contractile Force in a 3-D Model of Human Skeletal Muscle > S. Sheeza MUGHAL (Barcelona, Spain) 14:39 S12L4 Lost In Translation: Pathogenic translation of GGC repeats in novel and toxic proteins in Oculo-Pharyngo-Distal Myopathy (OPDM) > M. Manon BOIVIN (Illkirch, France) 14:42 S12L5 RyR1 content decrease-induced ER stress is a hallmark of myopathies > N. Nadège ZANOU (Lausanne) 14:45 S12L6 Elucidating CHCHD10 Mutant Phenotypes in Inducible Cell Models and Designing Effective Therapeutic Strategies > C. Christian LANTZ (Atglen, Pennsylvania, USA) 14:48 S12L7 PHF2 demethylase controls muscle stem cell fate modulating lipid droplets turnover > D. Delia CICCIARELLO (Lyon) 14:51 S12L8 Study of the role of muscle metabolism in Amyotrophic Lateral Sclerosis > F. Flore CHEGUILLAUME (Paris, France) 14:54 S12L9 Activation of the WNT-dependent fibrogenic program by C1s/r complement subunits in dystrophic muscle > S. Stefano BIRESSI (Trento, Italy) 14:57 S12L10 Muscle contributions to flunarizine-mediated beneficial effects in spinal muscular atrophy > S. Suzie LEFEBVRE (Paris, France) 15:00 S12L11 Imaging of muscle perfusion of dystrophic mice in situ with laser-speckle contrast analysis > L. Laurence NEFF (Geneva, Switzerland) 15:03 S12L12 Patients with Myotonic Dystrophy and GCC interruptions manifest late disease onset, greater proximal weakness, but similar neuromuscular, cardiac and CNS involvement as patients without interruptions > G. Gisela NOGALES GADEA (Barcelona, Spain) 15:06 S12L13 Live imaging reveals perturbed symmetric stem cell divisions in a mouse model of Duchenne Muscular Dystrophy > B. Brendan EVANO (Paris, France) 15:09 S12L14 Spatial restriction of dystrophin in skeletal muscle – implications for therapeutic interventions. > K. Katarzyna CHWALENIA (Oxford, UK) 15:12 S12L15 GDF5 overexpression improves pathophysiology of DMD in mdx mouse muscle > C. Christel GENTIL (Paris, France)
S13 16:00 > 17:30 PARALLEL SESSION 1 // OUTCOME MEASURES / PHYSIOTHERAPIES AMPHITHEATRE BORDEAUX
  • Chairman : E. Erik NIKS (Leiden, The Netherlands)
16:00 S13L1 Natural history studies : challenges and limitations > J-Y. Jean-Yves HOGREL (Paris, France) 16:30 S13L2 Natural history studies and clinical trial readiness: successes and future directions > L. Lindsay ALFANO (Columbus, USA) 17:00 S13L3 The validity of cardiopulmonary exercise testing for assessing aerobic capacity in neuromuscular diseases > E. Eric VOORN (Amsterdam, Netherlands) 17:15 S13L4 Longitudinal quantitative MRI of forearm and arm muscles in dysferlinopathy > H. Harmen REYNGOUDT (Paris, France)
S14 16:00 > 17:30 PARALLEL SESSION 2 // TITINOPATHIES AMPHITHEATRE HAVANE
  • Chairman : B. Bjarne UDD (Helsinki, Finland)
16:00 S14L1 Clinical Interpretation of Titin Variants > M. Marco SAVARESE (Helsinki, Finland) 16:30 S14L2 Recessive titinopathy: recently emerged ‘titan’of the paediatric muscle disease world > E. Emily OATES (Sydney, Australia) 17:00 S14L3 Personalized genetic counselling in titinopathies: exon usage as the key to gain prognostic insights in the whole clinical spectrum > M. Maria Francesca DI FEO (Genova, Italy) 17:15 S14L4 Distal upper limb onset titinopathy evolves towards a hereditary myopathy with early respiratory failure (HMERF) phenotype. > M. Mario FUENTEALBA (Concepcion, Chile)
SYMPO6 17:30 > 18:30 INDUSTRY SYMPOSIUM // ALEXION - Legacy and Innovation: The Potential of Complement in Myasthenia Gravis 352 A+B
17:30 SYMP6L1 Welcome and Introductions 17:35 SYMP6L2 Burden of Disease and Role of Complement in MG > A. Anthony BÉHIN (Paris, France) 17:43 SYMP6L3 Complement inhibition as a target for MG treatment > D. Djillali ANNANE (Paris, France) 18:03 SYMP6L4 MG Treatment guidelines in the context of Clinical Practice in France > A. Anthony BÉHIN (Paris, France) 18:13 SYMP6L5 Summary and close 18:28 SYMP6L6 Discussion and Q&A
ND 20:00 > 20:00 NETWORKING DINNER / BATEAUX-MOUCHES PARIS
Thursday, 25 April 2024
S15 08:30 > 10:00 PLENARY SESSION // GENE EDITING AMPHITHEATRE BORDEAUX
  • Chairman : A. Annemieke AARTSMA-RUS (Leiden, The Netherlands)
08:30 S15L1 Genome Editing for Duchenne Muscular Dystrophy > C. Charles GERSBACH (Durham, USA) 09:00 S15L2 N=1 DMD Gene Editing > R. Richard HORGAN (Woodbridge, CT, USA) 09:30 S15L3 Human iPS-based disease models and CRISPR-Cas technology for the development of genetic therapies for LMNA­-related skeletal muscle laminopathies > D. Daniel MOORE (London, UK) 09:45 S15L4 First correction by Prime editing of mutations in the RYR1 gene > J. Jacques P. TREMBLAY (Quebec, Canada)
B7 10:00 > 10:30 COFFEE BREAK AND VISIT OF THE EXHIBIT HALL AND POSTER ROOM Hall Havane AB
S16 10:30 > 12:00 PARALLEL SESSION 1 // METABOLIC DISORDERS AMPHITHEATRE BORDEAUX
  • Chairman : C. Claude DESNUELLE (Nice, France)
10:30 S16L1 Update on genetic causes of rhabdomyolysis and diagnostic strategy > P. Pascal LAFORET (Paris, France) 11:00 S16L2 New facets of Pompe disease > B. Benedikt SCHOSER (Munich, Germany) 11:30 S16L3 Decoding the transcriptome of late-onset Pompe disease muscle at single nucleus resolution > A. Alexandra MONCEAU (Newcastle-upon-Tyne) 11:45 S16L4 Abnormal autophagy is a critical mechanism in TANGO2-related rhabdomyolysis > H. Hortense DE CALBIAC (Paris, France)
S17 10:30 > 12:00 PARALLEL SESSION 2 // INFLAMMATORY MYOPATHIES AMPHITHEATRE HAVANE
  • Chairman : Y. Yves ALLENBACH (France)
10:30 S17L1 Myositis classification for targeted treatments > O. Olivier BENVENISTE (Paris, France) 11:00 S17L2 Pathological features of myositis > I. Ichizo NISHINO (Kodaira, Japan) 11:30 S17L3 Absence of gene pathogenic variants and strong association with HLA-DRB1*11:01 in statin-naïve early-onset anti-HMG-CoA reductase necrotizing myopathy > L. Laura LLANSO CALDENTEY (Barcelona, Spain) 11:45 S17L4 Proteomic profiling to define IIM-associated marker proteins in cultured human myoblasts > A. Andreas ROOS (Dusseldorf, Germany)
SYMPO7 12:00 > 13:00 INDUSTRY SYMPOSIUM // UCB - The contribution of real-life data in the perception of autoimmune myasthenia gravis 352 A+B
  • Chairman : E. Emmanuelle CAMPANA (Marseille, France)
SYMP7L1 Welcome and introduction SYMP7L2 What contributions does the SNDS make towards the definition of different populations of autoimmune myasthenia gravis? > C. Céline TARD (Lille, France) SYMP7L3 MyastheniaGravis, its Impact on QOL and Work in France (SPOON Study) : an innovative methodology to qualify patient needs. > M. Matthieu LUSIGNAN (Bordeaux, France)
B8 13:00 > 14:30 LIGHT LUNCH BUFFET (OFFERED) AND VISIT OF THE EXHIBIT HALL Hall Havane AB
S18 14:30 > 16:00 PARALLEL SESSION 1 // NEUROMUSCULAR JUNCTION AMPHITHEATRE BORDEAUX
  • Chairman : P. Pedro RODRIGUEZ (Dakar, Senegal)
14:30 S18L1 Emerging therapies for autoimmune myasthenia gravis > J. Jan VERSCHUUREN (Amsterdam, The Netherlands) 15:00 S18L2 Moving towards personalized medicine in Myasthenia Gravis through biomarkers and the power of physical exercise > A. Anna PUNGA (Uppsala, Sweden) 15:30 S18L3 Origin of the thymic interferon type I signature in myasthenia Gravis: role of endogenous nucleic acids > R. Rozen LE PANSE (Paris, France) 15:45 S18L4 Concomitant Corticosteroid Use in Ravulizumab-Treated Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-label Extension > D. Djillali ANNANE (Paris, France)
S19 14:30 > 16:00 PARALLEL SESSION 2 // MUSCLE AND MITOCHONDRIA AMPHITHEATRE HAVANE
  • Chairman : V. Vincent PROCACCIO (Angers, France)
14:30 S19L1 Mitochondrial medicine: from mechanisms to treatments > R. Rita HORVATH (Cambridge, UK) 15:00 S19L2 Mitochondrial disorders: current trials and emerging therapy options > T. Thomas KLOPSTOCK (Muenchen, Germany) 15:30 S19L3 Mitochondrial Myopathy caused by TK2 deficiency: lessons from a large Brazilian cohort. > C. Christiane ARAUJO (Sao Paolo, Brazil) 15:45 S19L4 Dissection of mechanisms underlying the pathogenesis of Duchenne Muscular Dystrophy > E. Elena CANNONE (Brescia, Italy)
S20 16:00 > 16:15 YOUNG RESEARCHERS AWARDS CEREMONY AMPHITHEATRE BORDEAUX
  • Chairmen : S. Serge BRAUN (Evry, France), T. Thierry TOURSEL (Evry, France)
S21 16:15 > 17:15 LATE BREAKING NEWS AMPHITHEATRE BORDEAUX
  • Chairman : J-F. Jean-François BRIAND (Evry, France)
16:15 S21L1 Initial Data from the DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping > E. Erwan DELAGE (Paris, France) 16:30 S21L2 Striking cardioprotective effects of AdipoRon in an aged mouse model of Duchenne Muscular Dystrophy > M. Michel ABOU-SAMRA (Brussels, Belgium) 16:45 S21L3 Optimising a multimodal pathway to discover genes involved in Satellite Cell-opathies: neuromuscular disorders caused by muscle stem cell dysfunction > P. Peter ZAMMIT (London, United Kingdom) 17:00 S21L4 Challenges in predicting the pathogenicity of SMCHD1 variants in light of disease penetrance in FSHD2 > F. Frederique MAGDINIER (Marseille, France)
S22 17:15 > 17:30 CLOSING CEREMONY AMPHITHEATRE BORDEAUX
Copyright © key4events - All rights reserved